Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P04637: Variant p.Leu330Pro

Cellular tumor antigen p53
Gene: TP53
Feedback?
Variant information Variant position: help 330 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Leucine (L) to Proline (P) at position 330 (L330P, p.Leu330Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In a sporadic cancer; somatic mutation. Any additional useful information about the variant.


Sequence information Variant position: help 330 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 393 The length of the canonical sequence.
Location on the sequence: help NNTSSSPQPKKKPLDGEYFT L QIRGRERFEMFRELNEALEL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         NNTS-SSPQPK--KKPL----DGEYFTLQIRGRERFEMFRELNEALEL

                              PSTS-SSPPQK--KKPL----DGEYFTLQIRGRERYEMFRN

Rhesus macaque                NNTS-SSPQPK--KKPL----DGEYFTLQIRGRERFEMFRE

Mouse                         TCTS-ASPPQK--KKPL----DGEYFTLKIRGRKRFEMFRE

Rat                           TSTS-SSPQQK--KKPL----DGEYFTLKIRGRERFEMFRE

Pig                           TSTS-SSPVQK--KKPL----DGEYFTLQIRGRERFEMFRE

Bovine                        TNTS-SSPQPK--KKPL----DGEYFTLQIRGFKRYEMFRE

Rabbit                        TTTTDSSPQTK--KKPL----DGEYFILKIRGRERFEMFRE

Sheep                         SSTS-SSPQQK--KKPL----DGEYFTLQIRGRKRFEMFRE

Cat                           PSTS-STPPQK--KKPL----DGEYFTLQIRGRERFEMFRE

Chicken                       PPTE-APEPPK--KRVL--NPDNEIFYLQVRGRRRYEMLKE

Xenopus laevis                PSSE--PPLPK--KRLVVVDDDEEIFTLRIKGRSRYEMIKK

Zebrafish                     ESSS-ATLRPEGSKKAKGSSSDEEIFTLQVRGRERYEILKK

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 393 Cellular tumor antigen p53
Region 100 – 370 Interaction with HIPK1
Region 300 – 393 Interaction with CARM1
Region 319 – 360 Interaction with HIPK2
Region 325 – 356 Oligomerization
Modified residue 315 – 315 Phosphoserine; by AURKA, CDK1 and CDK2
Modified residue 321 – 321 N6-acetyllysine
Modified residue 333 – 333 Omega-N-methylarginine; by PRMT5
Modified residue 335 – 335 Symmetric dimethylarginine; by PRMT5
Modified residue 337 – 337 Symmetric dimethylarginine; by PRMT5
Mutagenesis 319 – 319 K -> A. Loss of nuclear localization; when associated with A-320 and A-321.
Mutagenesis 320 – 320 K -> A. Loss of nuclear localization; when associated with A-319 and A-321.
Mutagenesis 321 – 321 K -> A. Loss of nuclear localization; when associated with A-319 and A-320.
Beta strand 327 – 334



Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.